Has Ruby Camarena received payments from drug or device companies?

Yes. Drug and device makers reported $3,237 in general payments to Ruby Camarena across 149 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ruby Camarena did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ruby Camarena come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ruby Camarena

Internal Medicine · Philadelphia, PANPI 1144203480

Payments from drug & device makers

$3,237in general payments, 2019–2025

Across 149 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$628
Johnson & Johnson$534
GSK$506
Merck$377
Lilly USA, LLC$198
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$182
plus $813 from 21 others

What the payments were for

Food & beverage$3,237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	37	$628
Johnson & Johnson(2 entities)	12	$534
GSK	21	$506
Merck	21	$377
Lilly USA, LLC	7	$198
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$182
Bayer	5	$94
Novo Nordisk	4	$88
Boehringer Ingelheim	6	$86
Viiv Healthcare Company	4	$68
Amgen	3	$63
Pfizer	2	$44
Regeneron Healthcare Solutions, Inc.	2	$41
Therapeuticsmd, Inc.	2	$40
Exeltis, USA Inc.	2	$35
Mylan Pharmaceuticals Inc.	2	$33
Lupin Inc.	2	$33
Sanofi Pasteur Inc.	2	$28
AbbVie	1	$26
Amarin Pharma, Inc.	2	$25
Phadia US Inc.	1	$19
Evofem Biosciences, Inc.	1	$19
E.r. Squibb & Sons, L.L.C.	1	$16
AstraZeneca	1	$15
BD	1	$14
Dynavax Technologies Corporation	1	$14
Hologic Inc	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,237 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	15	$13,200
Breo ElliptaFluticasone/Vilanterol	11	$5,151
Atorvastatin Calcium	114	$1,758
Albuterol Sulfate HfaAlbuterol Sulfate	38	$1,510
Ezetimibe	19	$1,434
Alcohol PadsAlcohol Antiseptic Pads	24	$896
Fluticasone Propionate	21	$755
Chlorthalidone	28	$637
Gabapentin	55	$634
Omeprazole	34	$619
Metformin Hcl	43	$576
Amlodipine Besylate	69	$537
Montelukast Sodium	21	$451
Losartan Potassium	35	$434
Pantoprazole Sodium	36	$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Boehringer IngelheimJardiance	$86	$13,20015 claims
GSKBreo Ellipta	$506	$5,15111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

Jonathan EpsteinPhiladelphia$13.1M
Pitamber DevgonPhiladelphia$7.5M
Walter KraftPhiladelphia$3.7M
Daniel RaderPhiladelphia$3.3M
Archna BajajPhiladelphia$2.9M
Gary YeomanPhiladelphia$2.4M
Melina MarmarelisPhiladelphia$2.1M
Adam WaxmanPhiladelphia$894K
Donna GavaronePhiladelphia$728K
Eyob FeyssaPhiladelphia$693K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →